Abstract
Background Pre-frailty and frailty prevalence is increasing in the Western Pacific, resulting in substantial morbidity and mortality in older populations. Modelling frameworks are required to estimate the prevalence of frailty and potential impacts of ongoing population level nutritional interventions.
Methods Using a microsimulation sociodemographic model of 3,353,032 individuals from 1990 to 2050, and data from the Singapore Longitudinal Ageing Study 2 of 3,270 participants, we developed a Bayesian multistate model of robust, pre-frailty and frailty stages with estimated transition probabilities by age, race, and gender for each body-mass index (BMI) category. We then explored four scenarios where nutritional and physical activity interventions are applied that modify the annual distribution of underweight, normal weight, overweight, obese I and obese II individuals.
Findings Between 2011 and 2050, the overall prevalence of pre-frailty and frailty increased from 44.2% to 50.5%, and from 3.2% to 11.8% respectively. Reductions of 9,529 pre-frail (95% CI: 7,303-11,673) and 6,960 frail individuals (6,094-7,886) were estimated when underweights shifted to normal weights, 11,598 (8,270-15,184) and 57,131 (39,258-82,696) when obese II moved to obese I, and 21,091 (16,179-25,846) and 63,891 (45,372-90,072) when both groups shifted respectively. Total healthcare utilization decreases by 6.9% (5.5%-8.3%) with the latter intervention.
Interpretation Frailty prevalence is projected to substantially increase by 2050 where large-scale weight management interventions could be utilised to avert cases of both pre-frailty and frailty in older individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Singapore Ministry of Health, National Innovation Challenge (NIC Ageing) Healthy Longevity Catalyst Awards (HLCA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at: https://pubmed.ncbi.nlm.nih.gov/30498830/ https://pubmed.ncbi.nlm.nih.gov/27576598/ http://www.singstat.gov.sg/find-data/search-by-theme/population/births-and-fertility/latest-data https://pmc.ncbi.nlm.nih.gov/articles/PMC3367999/ http://www.singstat.gov.sg/find-data/search-by-theme/population/death-and-life-expectancy/latest-data https://pubmed.ncbi.nlm.nih.gov/25452860/ https://tablebuilder.singstat.gov.sg/table/TS/M810801 https://hpb.gov.sg/community/national-population-health-survey/survey-findings
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
